12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Sun, 23 Nov 2025 18:41:05 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [7] => x-frame-options: SAMEORIGIN [8] => x-content-type-options: nosniff [9] => x-xss-protection: 1; mode=block [10] => referrer-policy: strict-origin-when-cross-origin [11] => permissions-policy: geolocation=(), microphone=(), camera=() [12] => content-security-policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => x-robots-tag: noindex, nofollow, nosnippet, noarchive [15] => strict-transport-security: max-age=31536000; includeSubDomains; preload [16] => expires: Mon, 24 Nov 2025 18:41:05 GMT [17] => vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=sz4aKX7J91K%2FE1LuBpjEphDryQJ%2Fy%2FY7tTVSAcXPE1eVzxhygrU%2BsHmWQ8gKoPj6%2F%2FSHdXPtUIqHkWnzypUP9xXpSXj7WktYF8%2BMaIw%3D"}]} [19] => cf-cache-status: DYNAMIC [20] => Speculation-Rules: "/cdn-cgi/speculation" [21] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [22] => Server-Timing: cfEdge;dur=2,cfOrigin;dur=104 [23] => Set-Cookie: UpalLiveSession=eyJpdiI6IlVQdmIyckFINmo1MW90TFRiZVo1S0E9PSIsInZhbHVlIjoib01wWDhVV0x3SmlWTEQrVjdOaXZMMTlIc0VVd09NUWVHZiszRTkrMWdFY21zMVpPYWpTZTRUbSsxWGhmZXdMU0lVY2JHemxcL203YVRDS1lHc2Y0bTJnPT0iLCJtYWMiOiIyZTk3NWI1MWFjNGRlMWFlMGFlNjI2OTYyNjRkY2UzMjQ5OGQ2NDk3YmZhYjBiZjJkNzc1YTg3ZGRjN2Q5Y2VhIn0%3D; HttpOnly; Path=/; Max-Age=94608000; Expires=Wed, 22 Nov 2028 18:41:05 GMT [24] => CF-RAY: 9a32cc78cae9c0c2-KUL [25] => alt-svc: h3=":443"; ma=86400 ) 789

美国于6日将用在研究的抗病毒药物瑞德西韦（Remdesivir），成功治愈新冠肺炎患者。

首批收治患者的武汉市金银潭医院，于周四启动美国新药的临床试验，为308名轻至中症患者、453名重症患者进行“双盲试验”，评估它的疗效和安全性。

该试验计划预计完成时间为今年4月27日，试验组和对照组在第1天分别给予瑞德西韦和安慰剂200毫克负荷剂量，然后每天一次100毫克静脉内维持剂量，持续9天。

试验专案负责人曹彬指出，由于瑞德西韦治疗的病例仅有1宗，加上其第1期、第2期安全性试验是在境外完成，与中国存在人种差异，故必须执行严格的随机双盲试验，患者与医生都不清楚所服用的究竟是试验药还是安慰剂，直至揭盲时才能确信药物效果。